38.22  0 (0%)		04-24 15:47
Open: 38.21 High: 38.24 Volume: 5,540,084		Pre. Close: 38.22 Low: 38.21 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Dicerna Pharmaceuticals, Inc. functions as a biopharmaceutical company primarily dedicated to the full spectrum of RNA interference (RNAi)-based drug development, from initial discovery to market commercialization. The firm leverages its exclusive GalXC RNAi platform to engineer therapeutic solutions for a diverse array of medical conditions. These include various liver-related ailments, spanning rare, cardiometabolic, viral, and chronic forms, alongside complement-mediated disorders, neurodegenerative diseases, and pain. Among its prominent development candidates are nedosiran, targeting primary hyperoxaluria; RG6346, designed for chronic hepatitis B virus infection; belcesiran, intended for deficiency-associated liver disease; and DCR-AUD, addressing alcohol use disorder. Dicerna has established significant collaborations with several leading pharmaceutical corporations, including Novo Nordisk A/S, F. Hoffmann-La Roche (both Ltd and Inc.), Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Founded in 2006 and based in Lexington, Massachusetts, Dicerna Pharmaceuticals, Inc. has been operating as a subsidiary of Novo Nordisk A/S since December 27, 2021.

Thu, 28 May 2026
EnPlusOne Adds Former Dicerna Executive Jim Weissman to Board as RNA Manufacturing Efforts Expand - citybiz

Tue, 24 Feb 2026
Small Interfering RNA (siRNA) Therapeutics Market Size to Hit USD 528.78 Billion by 2035 - Precedence Research

Thu, 04 Sep 2025
RNA Therapeutics Market Size, Share, Growth, Forecast, 2034 - Straits Research

Fri, 14 Jan 2022
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition - BioPharma APAC

Tue, 28 Dec 2021
Novo Nordisk completes acquisition of Dicerna Pharmaceuticals - Drug Delivery Business

Tue, 28 Dec 2021
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date